glp-1 news updates november 2025 Novo cuts prices 70%, but semaglutide revenue could grow in 2026 GLP-1 Pipeline Update: August 2025

Levia is a transdermal weight loss patch designed to support gradual and steady weight loss in a simple, non-invasive way

Avoid extreme temperatures and humidity

Preclinical studies have demonstrated that GLP-1 receptor agonists reduce neuroinflammation, reduce tau phosphorylation, reduce amyloid deposition, increase synaptic function, and improve memory formation

The low placental transfer could be caused by the release of Dipeptidyl peptidase IV positive syncytiotrophoblast-derived extracellular vesicles released by the human placenta which degrade GLP-1 in uterine blood (63), as well as to the high molecular weight of GLP-1 agonists (4 73 kDa)

Ready to navigate the future of chronic care